better right revlimid
messag wake bmi propos acquisit celg
publish new stand-alone model pro-forma accretion/dilut model
bmi above-consensu guidanc surpris us given busi trajectori
deal celg withstand current revlimid ip challeng settl
deal work financi strateg view growth investor still
pipelin longer pt given neutral rate
stand-alone model place bmi fair valu vs current post-
bmy-celg surpris us investorsad anoth layer uncertainti
morn announc neutral plan acquir celg
neutral cash stock transact potenti
rapidli substanti accret ep least current model revlimid
entri gener major surpris investor rais number question
bmy-specif question focus confid growth i/o
franchis today confer call question understand focus confid
growth bmi i/o franchis particularli sever key phase lung
kidney cancer readout approachher management emphas current strength
busi skin kidney lung cancer specif note recent im sale highlight
continu strength opdivo yervoy well registr
program underway read i/o portfolio within next month
provid strong base i/o portfolio futur growth potenti valu
realiz within bmi pipelin outsid manag note robust
earli stage program provid base growth acknowledg
import access potenti uniqu pipelin opportun celg
broader industri concern need consolid weather potenti
materi chang price well overal global growth assumptionsand
even though management sanguin emphas histori anticip chang
oper environ highlight area theyv exit like primari care viral diseas
celg risk combin focus revlimid patent challeng
celg growth would grow lose revlimid regard
premium previou day stock price assum announc transact
valu celg question focus on-going ipr challeng revlimid
patentsher bmi view consist celg patent upheld
settl valu revlimidin case assum rapid sale
declin revlimid valu ascrib celg base
busi vs synergi vs pipelinebmi note believ base busi
larg justifi pre-deal stock price synergi account major
rest deal key pipelin asset includ new indic
repres upsid transact regard tradeabl conting valu right cvr
emphas cvr requir three follow approv occur
follow approv treatment relaps refractori dlbcl
ozanimod approv relaps remit ms
approv relaps refractori multipl myeloma agre
ascrib rel modest valu fedratinib view luspatercept key pipelin
asset addit note prospect optim commerci prospect
advanc product inflammatori bowel disord like crohn ulcer coliti
beyond revlimid patent growth challeng combin compani
face revlimid gener enter market emphas see
potenti revenu highlight asset discuss balanc believ
page analyst certif import disclosur
continu biggest struggl face investor valu combin busi
go forward either long-term dcf long-term price-to-earnings multipl perspect
celg combin highli accret near medium term
base cost-synergi assumpt view key posit
deal near-term medium-term ep accret deal cash flow gener
expect exceed first three full year post-clos base
pro-forma model estim accret assum close
accret driven estim deal synergi estim
consensu celg growth assumpt modest contribut acceler share
repurchas post-deal close rel stand-alon estim estim
cost-synergi assum cog sg synergi
respect view signific risk deal accret ip risk around
revlimid given variou ip-rel litig proceed gener filer see
primari risk deal close come sharehold near-term dilut
share wake today announc transact
model reflect updat guidanc sale ep
updat model follow bmi announc ep guidanc
non-gaap basi bump sale estim
lower forecast primarili reflect opdivo/yervoy current
growth trajectori kidney cancer remov small-cel lung cancer contribut
given recent failur opdivo/yervoy combin see note net effect
chang posit effect ep estim near term low-double-digit
reduc ep estim low-mid-singl digit net-net estim place
bmi stand-alone fair valu dcf basi bmi ep guidanc includ
dilut upsa consum health divestitur us pension liabil transact
exclud impact celg acquisit compani provid full line-item
guidanc compani report result januari
page analyst certif import disclosur
page analyst certif import disclosur
newco sale adj cog estimate synergies- total combin gross profit estimate new adjust sg estimate new combin oper profit net incom /expens net debt interest paid mm acq debt interest interest total interest paid lost pro-forma pre-tax incom tax expens minor interest celg- net incom net -celg old share count new share issu total new share outstand deal summari stand-alon theoret -celg synergies- newco ratio sale global
valuat risk stand-alon basi
fair valu rang forecast sale profit use larg
pharmaceut compani discount rate line compani
coverag univers termin growth rate
upsid risk includ success develop opdivo combin lung cancer
better-than-expect opdivo/relatlimab result
disappoint ph result competitor i/o trial particularli buy rhhbi
downsid risk better-than-expect ph result i/o competitor clinic
failur mid- late-stag pipelin program
page analyst certif import disclosur
usd million except ep
page analyst certif import disclosur
